The purity of recombinant hNRG-1 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hNRG-1 and staining overnight with Coomassie Blue.Learn more about how we get our images
The proliferation of MCF7 cells treated with increasing concentrations of hNRG-1 was assessed. After a 7 day treatment with hNRG-1 cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.Learn more about how we get our images
Western blot analysis of extracts from MCF7 cells, untreated or treated with hNRG-1 for 7 minutes, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370 (upper) and p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (lower).Learn more about how we get our images
Recombinant human NRG-1 (hNRG-1) Thr176-Lys238 (Accession #NP_001153480) was produced in E. coli cells at Cell Signaling Technology.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hNRG-1. All lots are greater than 98% pure.
Recombinant hNRG-1 does not have a Met on the amino terminus and has a calculated MW of 7,284. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal TSHLV of recombinant hNRG-1 was verified by amino acid sequencing.
The bioactivity of recombinant hNRG-1 was determined in a cell proliferation assay using MCF7 cells. The ED50 of each lot is between 1-4 ng/ml.
Less than 0.01 ng endotoxin/1 μg hNRG-1.
With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hNRG-1. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
NRG-1, a member of the EGF family, is involved in heart, mammary and nervous system development (1). NRG-1 is expressed by mammary epithelial, vascular endothelial and neuronal cells (2,3). At least 15 NRG-1 splice variants are known (1). These variants differ in EGF domains (α or β variants), amino-terminal splicing sites, and incorporation of exons encoding integral membrane regions (1). NRG-1 can induce or inhibit the proliferation of cells derived from breast cancer. The differences in effects of NRG-1 appear to depend on splice variation and interaction with receptor(s) (2). NRG-1 binds to ErbB3/HER3 or ErbB4/HER4. Binding induces dimerization with ErB2/HER2. The Akt, Erk1/2 and Erk5 pathways have been shown to participate in NRG-1 activated signaling (4,5). NRG-1 appears to have roles in schizophrenia and breast cancer (1,4,6).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.
|5218SC||50 µg (With Carrier)||$211.00.0|
|5218SF||50 µg (Carrier Free)||$211.00.0|